OS of patients in separate cohorts. (A-B) The OS of 25 patients in the entire cohort (A) and in a separate cohort of CLL (“no” to RT) vs RT (”yes” to RT) patients (B). (C) The OS of patients in 2 cohorts separated by having prior ibrutinib or no prior ibrutinib treatment. OS of patients who had prior ibrutinib treatment (n = 15) separated by CLL vs RT is shown in panel D. NE, not ended.